Home » News » Press Releases 2007 » Phase 1 trial shows ATC has potential for combination therapy with Tipranavir
Phase 1 trial shows ATC has potential for combination therapy with Tipranavir
�
- Home
- Corporate
- Projects
- Clinical Trials
- News
- Investor Relations
- Presentations
- Poster XV11 HIV Drug Resistance Workshop June 2008
- Investor Presentation March 2008
- BIO CEO Investor Conference New York February 2008
- CROI Poster Boston 2008
- CEO Presentation AGM 2007
- Investor Presentation October 2007
- Investor Roadshow Presentation 2007
- Presentation by Dr Cahn IAS Conference July 2007
- Investor Roadshow Presentation March 2007
- HIV Glasgow Conference November 2006 Apricitabine Poster
- AGM CEO presentation 2006
- Investor Roadshow Presentation November 2006
- FAQs
- Avexa Demerger
- General
- Annual Report Information
- Shareholder Information
- How can I obtain/request an issuer statement?
- Am I a CHESS Sponsored Holder or an Issuer Sponsored Holder?
- I do not appear to be receiving any correspondence in connection with my Avexa shares. Why?
- I do not know my HIN/SRN. How can I find out?
- What is a SRN?
- I have received an issuer statement from Computershare Investor Services Pty Ltd but it does not app
- How do I transfer securities?
- How do I buy/sell securities and shares?
- What is a HIN?
- How do I find a broker?
- What is Avexa Limited's code for the Australia Stock Exchange (ASX)?
- I am moving house and need to change my address. How do I do this?
- How do I notify Avexa of any changes of personal details such as my address, bank details, name etc?
- Will I be charged if I require a re-print of information already provided from Computershare?
- How secure is the information I provide to Avexa's share registry Computershare Investor Services?
- What is Computershare's website address?
- Contact Us
Terms and Conditions |
Privacy Statement |
© 2008 Avexa Limited All Rights Reserved